Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Calcium-binding protein S100P promotes tumor progression but enhances chemosensitivity in breast cancer

Cong, Yizi, Cui, Yuxin, Wang, Suxia, Jiang, Lei ORCID:, Cao, Jianqiao, Zhu, Shiguang, Birkin, Emily, Lane, Jane ORCID:, Ruge, Fiona, Jiang, Wen G. ORCID: and Qiao, Guangdong 2020. Calcium-binding protein S100P promotes tumor progression but enhances chemosensitivity in breast cancer. Frontiers in Oncology 10 , 566302. 10.3389/fonc.2020.566302

[thumbnail of Cong+et+al+S100P+Frontiers+Oncology+2020+reprint+fonc-10-566302 (1).pdf]
PDF - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (4MB) | Preview


Background: Chemoresistance remains one of the obstacles to overcome in the treatment of breast cancer. S100 calcium-binding protein P (S100P) has been observed to be overexpressed in several cancers and has been associated with drug resistance, metastasis, and prognosis. However, the role of S100P in chemoresistance in breast cancer has not been thoroughly determined. Methods: Immunohistochemistry was used to evaluate the expression level of S100P protein in 22 pairs (pre-chemo and post-chemo) of breast cancer tissue from patients who underwent neoadjuvant chemotherapy. The influence of S100P on the biological behavior and chemosensitivity of breast cancer cells was then investigated. Results: The protein level of S100P in breast cancer tissue was significantly higher than in benign fibroadenoma (p<0.001). The S100P expression level was shown to be decreased by 46.55% after neoadjuvant chemotherapy (p=0.015). Subgroup analysis revealed that S100P reduction (57.58%) was mainly observed in the HER2+ tumors (p=0.027). Our in-vitro experiments showed that the knockdown of S100P suppressed the proliferation, adhesion, migration and invasion abilities of T47D and SK-BR-3 breast cancer cells. We further demonstrated that this knockdown increased the chemoresistance to paclitaxel and cisplatin in SK-BR-3 cells. We found that S100P exerted its function by activating NF-κB, CCND1 and Vimentin, but downregulating E-cadherin. Conclusions: S100P promotes the aggressive properties of breast cancer cells and may be considered as a promising therapeutic target. Moreover, S100P can be used to predict the therapeutic effect of chemotherapy in HER2+ breast cancer patients.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Additional Information: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license
Publisher: Frontiers Media
ISSN: 2234-943X
Funders: the Key Project of the Research and Devel¬opment Plan of Shandong Province (No.2018GSF118125) and Key Project of the Research and Development Plan of Yantai City (No.2017YD007) and Cardiff Medical Scholarship
Date of First Compliant Deposit: 26 August 2020
Date of Acceptance: 24 August 2020
Last Modified: 07 May 2023 01:23

Citation Data

Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics